PharmaResearch Co., Ltd. (KOSDAQ:214450)

South Korea · Delayed Price · Currency is KRW

349,000

+25,000 (7.72%)

Jun 29, 2026, 3:30 PM KST

-28.12% (1Y)

Market Cap	3.63T -26.3%
Revenue (ttm)	565.48B +44.1%
Net Income	176.52B +59.1%
EPS	15,857.94 +49.4%
Shares Out	10.39M
PE Ratio	22.01
Forward PE	20.10
Dividend	3,700.00 (1.14%)
Ex-Dividend Date	Dec 29, 2025

Volume	426,567
Open	334,000
Previous Close	324,000
Day's Range	334,000 - 367,500
52-Week Range	255,000 - 713,000
Beta	0.46
Analysts	Buy
Price Target	502,642.86 (+46.27%)
Earnings Date	Aug 7, 2026

About PharmaResearch

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults thro... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1993

Employees 542

Stock Exchange KOSDAQ

Ticker Symbol 214450

Full Company Profile

Financial Performance

In 2025, PharmaResearch's revenue was 536.29 billion, an increase of 53.18% compared to the previous year's 350.12 billion. Earnings were 165.12 billion, an increase of 79.39%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for 214450 stock is "Buy." The 12-month stock price target is ₩502,643, which is an increase of 46.27% from the latest price.

Price Target

₩502,643

(46.27% upside)

Analyst Consensus: Buy

Stock Forecasts